Bio News

AstraZeneca will pay Insitro $40 million (about 53.6 billion won) upfront. Insitro will use its artificial intelligence (AI) platform to identify drug targets for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathy. AstraZeneca will secure exclusive worldwide development rights to selected programs.

BIOBOOK TEAM
biobookmedia@biobook.co.krDaewoong Pharmaceutical’s Flodicitinib Achieves More Than 90% Target Occupancy in Phase 1 Trial
Aribio’s AR1001 Meets Primary Endpoint in Phase 3 Alzheimer’s Trial
GC녹십자 Signs MOU With Dongbang FTL to Collaborate on LNP Production
CG Oncology: Cretostimogene Cuts Bladder Cancer Recurrence Risk by 68%; FDA Filing to Expand
CG Oncology: 68% Lower Risk of Bladder Cancer Recurrence; Shares Surge 12%
U.S. FDA Rejects Summit and Akeso’s PD-1/VEGF Lung Cancer Drug